Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation

Cholangiocarcinoma (CCA) exhibits aggressive biological behavior and a poor prognosis. Gemcitabine (GEM)-based chemotherapy is the first-line chemotherapy for advanced CCA but has a response rate of only 20-30%. Therefore, investigating treatments to overcome GEM resistance in advanced CCA is crucia...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yi-Ru, Wu, Chiao-En, Jung, Shih-Ming, Huang, Shih-Chiang, Lin, Sheng-Hsuan, Chou, Wen-Chi, Chang, Yu-Chan, Chen, Ming-Huang, Hung, Tsai-Hsien, Yu, Alice L., Huang, Wen-Kuan, Yeh, Chun-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266071/
https://www.ncbi.nlm.nih.gov/pubmed/37324940
http://dx.doi.org/10.7150/ijbs.79126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266071/
https://www.ncbi.nlm.nih.gov/pubmed/37324940
http://dx.doi.org/10.7150/ijbs.79126

Ejemplares similares